vs
英特格（ENTG）与瑞思迈（RMD）财务数据对比。点击上方公司名可切换其他公司
瑞思迈的季度营收约是英特格的1.7倍（$1.4B vs $823.9M），瑞思迈净利率更高（27.6% vs 6.0%，领先21.6%），瑞思迈同比增速更快（11.0% vs -3.1%），瑞思迈自由现金流更多（$311.2M vs $134.0M），过去两年瑞思迈的营收复合增速更高（9.0% vs 3.4%）
英特格是面向半导体及其他高科技行业的材料供应商，全球员工约8000人，总部位于美国马萨诸塞州比勒里卡。公司在全球多国及地区布局生产、客户服务与研发设施，覆盖美国、加拿大、中国、德国、以色列、日本、马来西亚、新加坡、韩国、中国台湾等地。
瑞思迈是一家起源于澳大利亚、总部位于美国加利福尼亚州圣迭戈的医疗设备企业，主打可接入云端的呼吸类医疗设备，用于治疗睡眠呼吸暂停、慢性阻塞性肺病等呼吸道疾病，新冠疫情期间曾大量生产呼吸机等设备助力患者救治。
ENTG vs RMD — 直观对比
营收规模更大
RMD
是对方的1.7倍
$823.9M
营收增速更快
RMD
高出14.0%
-3.1%
净利率更高
RMD
高出21.6%
6.0%
自由现金流更多
RMD
多$177.2M
$134.0M
两年增速更快
RMD
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $823.9M | $1.4B |
| 净利润 | $49.4M | $392.6M |
| 毛利率 | 43.8% | 61.8% |
| 营业利润率 | 12.7% | 34.6% |
| 净利率 | 6.0% | 27.6% |
| 营收同比 | -3.1% | 11.0% |
| 净利润同比 | -51.7% | 13.9% |
| 每股收益（稀释后） | $0.33 | $2.68 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENTGRMD
| Q4 25 | $823.9M | $1.4B | ||
| Q3 25 | $807.1M | $1.3B | ||
| Q2 25 | $792.4M | $1.3B | ||
| Q1 25 | $773.2M | $1.3B | ||
| Q4 24 | $849.8M | $1.3B | ||
| Q3 24 | $807.7M | $1.2B | ||
| Q2 24 | $812.7M | $1.2B | ||
| Q1 24 | $771.0M | $1.2B |
净利润ENTGRMD
| Q4 25 | $49.4M | $392.6M | ||
| Q3 25 | $70.5M | $348.5M | ||
| Q2 25 | $52.8M | $379.7M | ||
| Q1 25 | $62.9M | $365.0M | ||
| Q4 24 | $102.2M | $344.6M | ||
| Q3 24 | $77.6M | $311.4M | ||
| Q2 24 | $67.7M | $292.2M | ||
| Q1 24 | $45.3M | $300.5M |
毛利率ENTGRMD
| Q4 25 | 43.8% | 61.8% | ||
| Q3 25 | 43.5% | 61.5% | ||
| Q2 25 | 44.4% | 60.8% | ||
| Q1 25 | 46.1% | 59.3% | ||
| Q4 24 | 45.6% | 58.6% | ||
| Q3 24 | 46.0% | 58.6% | ||
| Q2 24 | 46.2% | 58.5% | ||
| Q1 24 | 45.6% | 57.9% |
营业利润率ENTGRMD
| Q4 25 | 12.7% | 34.6% | ||
| Q3 25 | 15.2% | 33.4% | ||
| Q2 25 | 13.4% | 33.7% | ||
| Q1 25 | 15.8% | 33.0% | ||
| Q4 24 | 17.6% | 32.5% | ||
| Q3 24 | 16.9% | 31.6% | ||
| Q2 24 | 16.0% | 31.2% | ||
| Q1 24 | 15.3% | 31.3% |
净利率ENTGRMD
| Q4 25 | 6.0% | 27.6% | ||
| Q3 25 | 8.7% | 26.1% | ||
| Q2 25 | 6.7% | 28.2% | ||
| Q1 25 | 8.1% | 28.3% | ||
| Q4 24 | 12.0% | 26.9% | ||
| Q3 24 | 9.6% | 25.4% | ||
| Q2 24 | 8.3% | 23.9% | ||
| Q1 24 | 5.9% | 25.1% |
每股收益（稀释后）ENTGRMD
| Q4 25 | $0.33 | $2.68 | ||
| Q3 25 | $0.46 | $2.37 | ||
| Q2 25 | $0.35 | $2.58 | ||
| Q1 25 | $0.41 | $2.48 | ||
| Q4 24 | $0.67 | $2.34 | ||
| Q3 24 | $0.51 | $2.11 | ||
| Q2 24 | $0.45 | $1.97 | ||
| Q1 24 | $0.30 | $2.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $360.4M | $1.4B |
| 总债务越低越好 | $3.7B | $403.9M |
| 股东权益账面价值 | $4.0B | $6.3B |
| 总资产 | $8.4B | $8.5B |
| 负债/权益比越低杠杆越低 | 0.94× | 0.06× |
8季度趋势，按日历期对齐
现金及短期投资ENTGRMD
| Q4 25 | $360.4M | $1.4B | ||
| Q3 25 | $399.8M | $1.4B | ||
| Q2 25 | $376.8M | $1.2B | ||
| Q1 25 | $340.9M | $932.7M | ||
| Q4 24 | $329.2M | $521.9M | ||
| Q3 24 | $432.1M | $426.4M | ||
| Q2 24 | $320.0M | $238.4M | ||
| Q1 24 | $340.7M | $237.9M |
总债务ENTGRMD
| Q4 25 | $3.7B | $403.9M | ||
| Q3 25 | $3.8B | $408.7M | ||
| Q2 25 | $4.0B | $658.4M | ||
| Q1 25 | $4.0B | $663.1M | ||
| Q4 24 | $4.0B | $662.9M | ||
| Q3 24 | $4.1B | $667.6M | ||
| Q2 24 | $4.1B | $697.3M | ||
| Q1 24 | $4.2B | $997.0M |
股东权益ENTGRMD
| Q4 25 | $4.0B | $6.3B | ||
| Q3 25 | $3.9B | $6.1B | ||
| Q2 25 | $3.8B | $6.0B | ||
| Q1 25 | $3.7B | $5.5B | ||
| Q4 24 | $3.7B | $5.3B | ||
| Q3 24 | $3.6B | $5.2B | ||
| Q2 24 | $3.5B | $4.9B | ||
| Q1 24 | $3.4B | $4.6B |
总资产ENTGRMD
| Q4 25 | $8.4B | $8.5B | ||
| Q3 25 | $8.4B | $8.3B | ||
| Q2 25 | $8.4B | $8.2B | ||
| Q1 25 | $8.4B | $7.6B | ||
| Q4 24 | $8.4B | $7.1B | ||
| Q3 24 | $8.5B | $7.2B | ||
| Q2 24 | $8.3B | $6.9B | ||
| Q1 24 | $8.4B | $6.8B |
负债/权益比ENTGRMD
| Q4 25 | 0.94× | 0.06× | ||
| Q3 25 | 0.99× | 0.07× | ||
| Q2 25 | 1.05× | 0.11× | ||
| Q1 25 | 1.06× | 0.12× | ||
| Q4 24 | 1.08× | 0.13× | ||
| Q3 24 | 1.15× | 0.13× | ||
| Q2 24 | 1.18× | 0.14× | ||
| Q1 24 | 1.22× | 0.22× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.0M | $339.7M |
| 自由现金流经营现金流 - 资本支出 | $134.0M | $311.2M |
| 自由现金流率自由现金流/营收 | 16.3% | 21.9% |
| 资本支出强度资本支出/营收 | 7.0% | 2.0% |
| 现金转化率经营现金流/净利润 | 3.89× | 0.87× |
| 过去12个月自由现金流最近4个季度 | $396.2M | $1.8B |
8季度趋势，按日历期对齐
经营现金流ENTGRMD
| Q4 25 | $192.0M | $339.7M | ||
| Q3 25 | $249.5M | $457.3M | ||
| Q2 25 | $113.5M | $538.8M | ||
| Q1 25 | $140.4M | $578.7M | ||
| Q4 24 | $176.1M | $308.6M | ||
| Q3 24 | $197.2M | $325.5M | ||
| Q2 24 | $111.2M | $440.1M | ||
| Q1 24 | $147.2M | $402.0M |
自由现金流ENTGRMD
| Q4 25 | $134.0M | $311.2M | ||
| Q3 25 | $182.8M | $414.4M | ||
| Q2 25 | $47.0M | $508.2M | ||
| Q1 25 | $32.4M | $557.9M | ||
| Q4 24 | $68.6M | $288.0M | ||
| Q3 24 | $115.0M | $307.7M | ||
| Q2 24 | $51.9M | $415.2M | ||
| Q1 24 | $80.6M | $380.8M |
自由现金流率ENTGRMD
| Q4 25 | 16.3% | 21.9% | ||
| Q3 25 | 22.6% | 31.0% | ||
| Q2 25 | 5.9% | 37.7% | ||
| Q1 25 | 4.2% | 43.2% | ||
| Q4 24 | 8.1% | 22.5% | ||
| Q3 24 | 14.2% | 25.1% | ||
| Q2 24 | 6.4% | 33.9% | ||
| Q1 24 | 10.4% | 31.8% |
资本支出强度ENTGRMD
| Q4 25 | 7.0% | 2.0% | ||
| Q3 25 | 8.3% | 3.2% | ||
| Q2 25 | 8.4% | 2.3% | ||
| Q1 25 | 14.0% | 1.6% | ||
| Q4 24 | 12.7% | 1.6% | ||
| Q3 24 | 10.2% | 1.5% | ||
| Q2 24 | 7.3% | 2.0% | ||
| Q1 24 | 8.6% | 1.8% |
现金转化率ENTGRMD
| Q4 25 | 3.89× | 0.87× | ||
| Q3 25 | 3.54× | 1.31× | ||
| Q2 25 | 2.15× | 1.42× | ||
| Q1 25 | 2.23× | 1.59× | ||
| Q4 24 | 1.72× | 0.90× | ||
| Q3 24 | 2.54× | 1.05× | ||
| Q2 24 | 1.64× | 1.51× | ||
| Q1 24 | 3.25× | 1.34× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
RMD
| Sleep And Breathing Health | $1.3B | 88% |
| Residential Care Software | $166.9M | 12% |
